Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of methyl genipin in preparation of medicine for treating or preventing obesity and obesity metabolic syndromes

A technology for methyl genipin and metabolic syndrome, applied in metabolic diseases, drug combinations, pharmaceutical formulas, etc., can solve problems such as limiting therapeutic effects, and achieve the effects of enhancing therapeutic effects, reducing liver damage effects, and good therapeutic effects

Active Publication Date: 2020-12-08
JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Recent studies have shown that genipin can improve the disturbance of glucose metabolism, tricarboxylic acid cycle and lipid metabolism in a diabetic rat model (Shen et al., 2016), and inhibit the growth of HepG2 hepatocytes after free fatty acid (FFA) treatment. Lipid accumulation (FFA; Kojima et al., 2011), has a significant effect on diet-induced obesity in rats (Lili Guan et al., 2017). However, in recent years, a large number of literatures have reported that genipin has severe liver damage effects , which greatly limits the therapeutic effects of genipin as a drug in all aspects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of methyl genipin in preparation of medicine for treating or preventing obesity and obesity metabolic syndromes
  • Application of methyl genipin in preparation of medicine for treating or preventing obesity and obesity metabolic syndromes
  • Application of methyl genipin in preparation of medicine for treating or preventing obesity and obesity metabolic syndromes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Embodiment 1: the preparation of genipin methyl

[0028] Take 100g of genipin, dissolve it in 300mL of methanol, quickly add 300mL of 2mol / L methanolic hydrochloric acid solution under stirring, continue to stir and react at room temperature for 10min, immediately pour it into water saturated with ethyl acetate, mix well, and use Ethyl acetate was extracted twice, the organic layers were combined, washed with water five times, and evaporated to dryness under reduced pressure. The residue was subjected to silica gel column chromatography and eluted with petroleum ether-ethyl acetate mixed solvent gradient to obtain genipin methyl.

Embodiment 2

[0029] Embodiment 2: Hepatotoxicity comparison between genipin and methylgenipin

[0030] 2.1 Materials

[0031] Genipin (Xi'an Lvzhiyin Biotechnology Co., Ltd.), and genipin methyl were prepared in Example 1.

[0032] 2.2 Administration and grouping

[0033] All medicines were made into 3 g / L gastric lavage solution with 0.5% carboxymethylcellulose sodium (CMC-Na) solution before use. DIO rats were randomly divided into 4 groups according to body weight; genipin group (n=10) by 20mg / kg / d ig; methylgenipin group (n=10) by 20mg / kg / d ig; blank group (n=10) and model group (n=10) ig equal amount of CMC-Na solution. Continuous administration for 4 weeks.

[0034] 2.3 Observation indicators

[0035] 2.3.1 Abnormal symptoms

[0036] The daily performance of experimental animals in each group was observed and recorded from time to time every day. Observe whether the animals have abnormal performance and symptoms before and after treatment.

[0037] 2.3.2 Body weight and Lee's...

Embodiment 3

[0063] Example 3: Pharmacodynamic study of genipin methyl, orlistat and their combination

[0064] 3.1 Materials

[0065] Orlistat Capsules (Chongqing Huasen Pharmaceutical Co., Ltd.), and genipin methyl are made by Example 1.

[0066] 3.2 Grouping and administration

[0067] Methylgenipin group (n=10) by 20mg / kg / d ig; orlistat group (n=10) by 20mg / kg / dig; orlistat+methylgenipin group: Listat: methyl genipin mass ratio (abbreviated as O: A) = 5:1, 2:1, 1:1, 1:2, 1:5, the total dosage remains orlistat + methyl Genipin=20mg / kg / d, ig, a total of 5 groups, each group n=10; model group (n=10) and blank group (n=10) ig equal amount of CMC-Na solution. Continuous administration for 4 weeks.

[0068] 3.3 Observation indicators

[0069] 3.3.1 Body weight and Lee's index

[0070] The animals were weighed once before and after treatment, and the body length (length from nose to anus) and abdominal circumference were accurately measured under anesthesia before sacrifice, according t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of methyl genipin in preparation of a medicine for treating or preventing obesity diseases. Research results in the invention show that: compared with genipin, methyl genipin not only has an obvious weight losing effect, but also has almost no damage effect on the liver. The invention further discloses a pharmaceutical composition of the methyl genipin and orlistat. Results show that the combined utilization of the methyl genipin and the orlistat has an obvious synergistic effect in treating obesity diseases, and has important significance in providing a newcandidate compound for treating obesity.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of methylgenipin in the preparation of medicines for treating or preventing obesity and obesity metabolic syndrome. Background technique [0002] Obesity is defined as abnormal or excessive fat accumulation that can impair health. It has become popular all over the world due to the excess energy intake and sedentary life of modern society. Obese adults (ages 18+) increased from 105 million in 1975 to 641 million in 2014 (NCD Risk Factor Collaboration, 2016). Furthermore, obesity is a risk factor for many metabolic disorders, such as diabetes, hypertension, and nonalcoholic fatty liver disease, and thus has become a major global health problem. Although pharmacotherapy plays an important role in the treatment of obesity, traditional anti-obesity drugs have been found to have adverse side effects (Dodson et al., 2013). Therefore, the discovery of safe and effect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61K31/365A61P3/06A61P1/16A61P3/10A61P3/04A61P5/48
CPCA61K31/352A61K31/365A61P1/16A61P3/04A61P3/06A61P3/10A61P5/48A61K2300/00
Inventor 余日跃黄丽萍周凤谢志忻刘红宁
Owner JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE